ANAHEIM - For the first time, researchers appear to be able to use a comprehensive panel of genetic variants to predict how a patient with esophageal cancer will respond to a spectrum of cancer treatments.
At the annual meeting of the American Association for Cancer Research (AACR), researchers from The University of Texas M. D. Anderson Cancer Center report that six different gene variants can predict an improved outcome in patients treated with two different chemotherapy drugs and/or with radiation therapy.
For example, the researchers say that a combination of several gene variants in patients treated with one type of chemotherapy (5-FU) more than doubled survival to 51 months, compared to 25 months in patients treated with the same drug who did not have these variants.
They say the findings represent a leap forward in the goal to provide tailored therapy to individual patients because it offers a genetic blueprint for gauging the potential effectiveness of all common esophageal cancer treatment, not just an analysis of how one or two "candidate" genes respond to a single treatment.
"Our data strongly suggest that combined pathway-based analysis may provide powerful clinical outcome predictors for esophageal cancer as well as for other cancers," says the study's lead author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology.
"This points to a promising new direction for cancer pharmacogenetics," she says. "Our hope is to have a gene chip one day that can analyze a patient's genetic makeup and help physicians predict response to a wide variety of therapeutic drugs before treatment even begins."
Esophageal cancer is highly aggressive; approximately 14,520 new esophageal cancer cases and 13,570 associated deaths are expected in 2005, according to the American Cancer Society. Almost half of new cases are diagnosed at an advanced stage, when the five-year survival rate is just 14 percent. Surgery is offered to most patients, as well as one or all of the following treatments - an anti-metabolite chemotherapy agent (5FU), an alkylating agent (cisplatin) and radiation treatment.
Knowing that variations exist in how a person biologically processes those therapies, the researchers collected tissue samples from 210 esophageal cancer patients. They then developed a "pathway analysis" that examined variants in 40 different genes believed to be involved in metabolism, DNA damage repair activity and action of these of therapies. Next, they compared differences in gene variants with outcomes in patients.
"This was like putting together a recipe, searching for different ingredients that work well together for patients," Wu says.
They found that patients with the best outcomes were those who had gene variants that were less effective at neutralizing the killing power of the cancer treatments. Conversely, patients whose genes efficiently counteracted chemotherapy and radiation treatment had shorter survival times overall.
- For 5FU treatment, patients who had two different variants (AC and AA) in the MTHFR gene pathway that metabolizes folate, the drug's active ingredient, had significantly improved survival (a median of 51 months) and a longer time to recurrence (36 months) compared to patients with the AA genotype (25 months and 17 months, respectively). "That makes sense because the AC and AA variant genes are less effective in metabolizing folate, which enables the drug to work better," Wu says.
- Significantly reduced recurrence rates and improved survival also were seen in patients treated with cisplatin who had particular variants of a multi-drug resistance gene (MDR). Proteins produced by this gene prevent cisplatin from entering cancer cells, and variants of the gene (CT and TT) that are less effective at doing so provide more therapeutic benefit to patients, Wu says. Patients with CT variant had a median survival of 29 months and those with a TT variant survived an average of 42 months. On the other hand, patients with the CC variant survived an average of just 17 months.
- The same pattern held true in analyzing genetic response to radiation treatment. Patients who had inherited less effective variants of a base excision repair gene (XRCC1) that repairs DNA damage from radiation exhibited longer survival. Those with the GG variant had a median survival of more than 57 months, compared to almost 23 months for patients with a GA variant and only 14 months for those with an AA variant.
The researchers also discovered an additive effect between these genes and others that conferred smaller advantages. The higher the number of beneficial variants the patient had, the longer survival was, they found.
As promising as the study is, significant hurdles remain before these findings can be incorporated into treatment, Wu says. Because more data are needed to support their findings, the investigators are accumulating a cohort of 800 esophageal patients from which they can draw a comprehensive genetic profile using blood samples.
If successful, such pathway-based analyses can be conducted for the wide variety of cancers that are treated with 5FU, cisplatin and radiation, as well as other drug treatments, Wu says.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Sell crazy someplace else. We're all stocked up here.
-- As Good As It Gets